Uroxatral
Brand names,
Uroxatral
Analogs
Uroxatral
Brand Names Mixture
Uroxatral
Chemical_Formula
C19H27N5O4
Uroxatral
RX_link
http://www.rxlist.com/cgi/generic3/uroxatral.htm
Uroxatral
fda sheet
Uroxatral
msds (material safety sheet)
Uroxatral
Synthesis Reference
No information avaliable
Uroxatral
Molecular Weight
389.449 g/mol
Uroxatral
Melting Point
No information avaliable
Uroxatral
H2O Solubility
No information avaliable
Uroxatral
State
Solid
Uroxatral
LogP
1.604
Uroxatral
Dosage Forms
Tablet (extended-release)
Uroxatral
Indication
For the treatment of the signs and symptoms of benign prostatic hyperplasia.
Uroxatral
Pharmacology
Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.
Uroxatral
Absorption
Absorption is 50% lower under fasting conditions
Uroxatral
side effects and Toxicity
side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
Uroxatral
Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/uroxatral_pi.htm
http://www.rxlist.com/cgi/generic3/uroxatral_wcp.htm
http://www.drugs.com/cons/Alfuzosin.html
Uroxatral
Organisms Affected
Humans and other mammals